Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical
Oncology Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is
not intended to substitute for the independent professional judgment of the treating physician.
Practice guidelines do not account for individual variation among patients. is pocket guide
does not purport to suggest any particular course of medical treatment. Use of the practice
guidelines and this resource are voluntary. e practice guidelines and additional information
are available at www.asco.org/breast-cancer-guidelines. Copyright ©2021 by American Society
of Clinical Oncology. All rights reserved.
Source
Tung NM, Boughey JC, Pierce LJ, et al. Management of Hereditary Breast Cancer: ASCO,
ASTRO, and SSO Guideline. J Clin Oncol. 2020 April 3 doi: 10.1200/JCO.20.00299
Tung NM, Somerfield MR, Boughey JC, et al. Adjuvant PARP Inhibitors in Patients with
High-risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations:
ASCO Guideline Recommendation Update. J Clin Oncol. 2021 August 3 doi: 10.1200/
JCO.21.01532
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2021 All rights reserved
ASCOTUNG7212a
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical
tools and resources, is available at www.asco.org/breast-cancer-guidelines.
Abbreviations
BCT, breast conserving therapy; CBC, contralateral breast cancer; CRRM, contralateral
risk-reducing mastectomy; HER2, human epidermal growth factor receptor 2; MRI,
magnetic resonance imaging ; PARP, Poly (ADP-ribose) polymerase; TNBC, triple negative
breast cancer
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength of
Recommendation
EB Evidence-
based
B Benefits
outweigh harms
H High Strong
FC
Formal
consensus
H Harms
outweigh
benefits
I Intermediate Moderate
IC Informal
consensus
B/H Relative balance
of benefits and
harms
L Low Weak
Ins Insufficient
